Literature DB >> 18724073

Targeting human mast cells expressing g-protein-coupled receptors in allergic diseases.

Yoshimichi Okayama1, Hirohisa Saito, Chisei Ra.   

Abstract

The G-protein-coupled receptors (GPCRs) are the largest known group of integral membrane receptor proteins and are the most common targets of pharmacotherapy. Mast cells (MCs) have been reported to play an important role in allergic diseases, such as urticaria and bronchial asthma. There is an increasing body of clinical evidence that MCs are recruited into allergic reactions by non-IgE-dependent mechanisms. Human MCs are activated and secrete histamine in response to neuropeptides, such as substance P and somatostatin, mediated by a GPCR, MRGX2. The microenvironment surrounding MCs in their resident tissues is likely to contain multiple factors that modify antigen-dependent MC activation. MCs express various GPCRs, and since the function of human MCs is modulated by various GPCR ligands, such as adenosine and sphingosine-1-phosphate, which are present in high levels in the bronchial alveolar lavage fluid of asthmatic patients, the GPCRs expressed on MCs may play an important role in human allergic diseases. The GPCRs expressed on MCs may serve as drug targets for the treatment of allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724073     DOI: 10.2332/allergolint.R-08-163

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  10 in total

1.  P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells.

Authors:  Zhan-Guo Gao; Yi Ding; Kenneth A Jacobson
Journal:  Pharmacol Res       Date:  2010-09-08       Impact factor: 7.658

2.  The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells.

Authors:  Zhan-Guo Gao; Qiang Wei; M P Suresh Jayasekara; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2012-07-24       Impact factor: 3.765

3.  Ligands and Signaling of Mas-Related G Protein-Coupled Receptor-X2 in Mast Cell Activation.

Authors:  Yan-Ni Mi; Na-Na Ping; Yong-Xiao Cao
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 4.  Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases.

Authors:  Hariharan Subramanian; Kshitij Gupta; Hydar Ali
Journal:  J Allergy Clin Immunol       Date:  2016-07-20       Impact factor: 10.793

5.  UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation.

Authors:  Zhan-Guo Gao; Yi Ding; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2009-11-05       Impact factor: 5.858

6.  Intermediary quantitative traits--an alternative in the identification of disease genes in asthma?

Authors:  M Sargurupremraj; K Pukelsheim; T Hofer; M Wjst
Journal:  Genes Immun       Date:  2013-10-17       Impact factor: 2.676

7.  Novel identified receptors on mast cells.

Authors:  Helena Migalovich-Sheikhet; Sheli Friedman; David Mankuta; Francesca Levi-Schaffer
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

8.  Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation.

Authors:  Noam Rudich; Katya Ravid; Ronit Sagi-Eisenberg
Journal:  Front Immunol       Date:  2012-06-04       Impact factor: 7.561

9.  Pathophysiological Roles of Neuro-Immune Interactions between Enteric Neurons and Mucosal Mast Cells in the Gut of Food Allergy Mice.

Authors:  Tomoe Yashiro; Hanako Ogata; Syed Faisal Zaidi; Jaemin Lee; Shusaku Hayashi; Takeshi Yamamoto; Makoto Kadowaki
Journal:  Cells       Date:  2021-06-23       Impact factor: 6.600

10.  Abnormalities in Gut Microbiota and Metabolism in Patients With Chronic Spontaneous Urticaria.

Authors:  Xin Wang; Wanyu Yi; Liting He; Shuaihantian Luo; Jiaqi Wang; Li Jiang; Hai Long; Ming Zhao; Qianjin Lu
Journal:  Front Immunol       Date:  2021-10-15       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.